martes, 26 de enero de 2021

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial - The Lancet Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial - The Lancet Infectious Diseases

No hay comentarios:

Publicar un comentario